Trial of JYB1904 in Patients With Allergic Asthma

Last updated: May 5, 2025
Sponsor: Jemincare
Overall Status: Active - Not Recruiting

Phase

2

Condition

Allergy (Pediatric)

Asthma

Treatment

Omalizumab

JYB1904

Clinical Study ID

NCT06438757
JYB1904-201
  • Ages 18-75
  • All Genders

Study Summary

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Able to provide written informed consent voluntarily;

  • Aged 18-75 years, weight ≥ 40 kg, male or female;

  • Diagnosed Allergic asthma.

Exclusion

Exclusion Criteria:

  • Prior exposure to anti-IgE therapy within 1 year;

  • Allergic to anti-IgE biologics;

  • Current smokers, or quit smoking within 1 year;

  • Combined with other non-allergic diseases that cause IgE elevation;

  • History of malignancy, autoimmune diseases, Immune complex mediated diseases,Hypereosinophilic syndrome;

  • Other conditions unsuitable for the trial judged by the investigator.

Study Design

Total Participants: 69
Treatment Group(s): 2
Primary Treatment: Omalizumab
Phase: 2
Study Start date:
June 19, 2024
Estimated Completion Date:
October 31, 2025

Connect with a study center

  • Shanghai General Hospital

    Shanghai, Shanghai 201203
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.